Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Total Current Liabilities (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Total Current Liabilities for 7 consecutive years, with $7.8 million as the latest value for Q3 2024.

  • On a quarterly basis, Total Current Liabilities fell 10.57% to $7.8 million in Q3 2024 year-over-year; TTM through Sep 2024 was $7.8 million, a 10.57% decrease, with the full-year FY2023 number at $8.5 million, down 20.08% from a year prior.
  • Total Current Liabilities was $7.8 million for Q3 2024 at Actinium Pharmaceuticals, down from $9.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $10.6 million in Q4 2022 to a low of $3.9 million in Q2 2021.
  • A 4-year average of $7.3 million and a median of $7.9 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: soared 99.28% in 2022, then dropped 20.08% in 2023.
  • Actinium Pharmaceuticals' Total Current Liabilities stood at $6.8 million in 2021, then skyrocketed by 55.38% to $10.6 million in 2022, then dropped by 20.08% to $8.5 million in 2023, then fell by 8.7% to $7.8 million in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Total Current Liabilities are $7.8 million (Q3 2024), $9.7 million (Q2 2024), and $8.1 million (Q1 2024).